China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand Life Sciences for its monoclonal antibody, KN057. This innovative therapy targets the tissue factor pathway inhibitor (TFPO) and is aimed at treating hemophilia A and hemophilia B in the Greater China region.
Agreement Details and Financial Commitments
Under the terms of the agreement, Alphamab will retain responsibility for conducting clinical studies, submitting market approval filings, and supplying the product. Grand Life Sciences will handle market promotion and commercial sales of KN057 in Greater China. As part of the deal, Grand will pay Alphamab up to RMB 500 million (approximately USD 69.5 million) in rights payments, which include both upfront and milestone payments. Additionally, tiered royalties will be paid on sales of the drug.
Progress in Clinical Development
KN057 has successfully passed Phase II clinical trials, demonstrating its potential as a treatment for hemophilia. This partnership aims to leverage both companies’ strengths to expedite the commercialization of KN057, enhancing patient access to this important therapy in the region.-Fineline Info & Tech
